Tags

Type your tag names separated by a space and hit enter

Vitreous and Vision Degrading Myodesopsia.
Prog Retin Eye Res. 2020 Mar 06 [Online ahead of print]PR

Abstract

Macromolecules comprise only 2% of vitreous, yet are responsible for its gel state, transparency, and physiologic function(s) within the eye. Myopia and aging alter collagen and hyaluronan association causing concurrent gel liquefaction and fibrous degeneration. The resulting vitreous opacities and collapse of the vitreous body during posterior vitreous detachment are the most common causes for the visual phenomenon of vitreous floaters. Previously considered innocuous, the vitreous opacities that cause floaters sometimes impact vision by profoundly degrading contrast sensitivity function and impairing quality-of-life. While many people adapt to vitreous floaters, clinically significant cases can be diagnosed with Vision Degrading Myodesopsia based upon echographic assessment of vitreous structure and by measuring contrast sensitivity function. Perhaps due to the ubiquity of floaters, the medical profession has to date largely ignored the plight of those with Vision Degrading Myodesopsia. Improved diagnostics will enable better disease staging and more accurate identification of severe cases that merit therapy. YAG laser treatments may occasionally be slightly effective, but vitrectomy is currently the definitive cure. Future developments will usher in more informative diagnostic approaches as well as safer and more effective therapeutic strategies. Improved laser treatments, new pharmacotherapies, and possibly non-invasive optical corrections are exciting new approaches to pursue. Ultimately, enhanced understanding of the underlying pathogenesis of Vision Degrading Myodesopsia should result in prevention, the ultimate goal of modern Medicine.

Authors+Show Affiliations

VMR Institute for Vitreous Macula Retina, Huntington Beach, CA, USA; Doheny Eye Institute, Pasadena, CA, USA; Department of Ophthalmology, Geffen School of Medicine, University of California, Los Angeles, CA, USA. Electronic address: jsebag@VMRinstitute.com.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

32151758

Citation

Sebag, J. "Vitreous and Vision Degrading Myodesopsia." Progress in Retinal and Eye Research, 2020, p. 100847.
Sebag J. Vitreous and Vision Degrading Myodesopsia. Prog Retin Eye Res. 2020.
Sebag, J. (2020). Vitreous and Vision Degrading Myodesopsia. Progress in Retinal and Eye Research, 100847. https://doi.org/10.1016/j.preteyeres.2020.100847
Sebag J. Vitreous and Vision Degrading Myodesopsia. Prog Retin Eye Res. 2020 Mar 6;100847. PubMed PMID: 32151758.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Vitreous and Vision Degrading Myodesopsia. A1 - Sebag,J, Y1 - 2020/03/06/ PY - 2019/09/22/received PY - 2020/03/01/revised PY - 2020/03/03/accepted PY - 2020/3/11/pubmed PY - 2020/3/11/medline PY - 2020/3/11/entrez KW - Contrast sensitivity function KW - Myopia KW - PVD KW - Vision degrading myodesopsia KW - Vitrectomy KW - Vitreous SP - 100847 EP - 100847 JF - Progress in retinal and eye research JO - Prog Retin Eye Res N2 - Macromolecules comprise only 2% of vitreous, yet are responsible for its gel state, transparency, and physiologic function(s) within the eye. Myopia and aging alter collagen and hyaluronan association causing concurrent gel liquefaction and fibrous degeneration. The resulting vitreous opacities and collapse of the vitreous body during posterior vitreous detachment are the most common causes for the visual phenomenon of vitreous floaters. Previously considered innocuous, the vitreous opacities that cause floaters sometimes impact vision by profoundly degrading contrast sensitivity function and impairing quality-of-life. While many people adapt to vitreous floaters, clinically significant cases can be diagnosed with Vision Degrading Myodesopsia based upon echographic assessment of vitreous structure and by measuring contrast sensitivity function. Perhaps due to the ubiquity of floaters, the medical profession has to date largely ignored the plight of those with Vision Degrading Myodesopsia. Improved diagnostics will enable better disease staging and more accurate identification of severe cases that merit therapy. YAG laser treatments may occasionally be slightly effective, but vitrectomy is currently the definitive cure. Future developments will usher in more informative diagnostic approaches as well as safer and more effective therapeutic strategies. Improved laser treatments, new pharmacotherapies, and possibly non-invasive optical corrections are exciting new approaches to pursue. Ultimately, enhanced understanding of the underlying pathogenesis of Vision Degrading Myodesopsia should result in prevention, the ultimate goal of modern Medicine. SN - 1873-1635 UR - https://www.unboundmedicine.com/medline/citation/32151758/Vitreous_and_Vision_Degrading_Myodesopsia L2 - https://linkinghub.elsevier.com/retrieve/pii/S1350-9462(20)30019-7 DB - PRIME DP - Unbound Medicine ER -
Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.